Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immuneering Corporation (IMRX : NSDQ)
 
 • Company Description   
Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

Number of Employees: 66

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.14 Daily Weekly Monthly
20 Day Moving Average: 169,408 shares
Shares Outstanding: 35.99 (millions)
Market Capitalization: $41.02 (millions)
Beta: -0.22
52 Week High: $3.83
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.63% -16.26%
12 Week -38.71% -33.79%
Year To Date -48.18% -46.15%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
245 MAIN STREET SECOND FLOOR
-
CAMBRIDGE,MA 02142
USA
ph: 617-500-8080
fax: -
ir@immuneering.com http://www.immuneering.com
 
 • General Corporate Information   
Officers
Benjamin J. Zeskind - Chief Executive Officer; President and Director
Mallory Morales - Chief Accounting Officer and Treasurer
Ann E. Berman - Director
Robert J. Carpenter - Director
Peter Feinberg - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45254E107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 35.99
Most Recent Split Date: (:1)
Beta: -0.22
Market Capitalization: $41.02 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.65 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.98
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 14.29%
vs. Previous Quarter: 27.59%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/25 - -119.22
12/31/24 - -100.00
09/30/24 - -79.19
ROA
03/31/25 - -99.22
12/31/24 - -85.26
09/30/24 - -69.08
Current Ratio
03/31/25 - 7.48
12/31/24 - 5.28
09/30/24 - 7.99
Quick Ratio
03/31/25 - 7.48
12/31/24 - 5.28
09/30/24 - 7.99
Operating Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Net Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Pre-Tax Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Book Value
03/31/25 - 1.16
12/31/24 - 1.33
09/30/24 - 1.95
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - 0.00
12/31/24 - 0.00
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - 0.00
12/31/24 - 0.00
09/30/24 - 0.00
 

Powered by Zacks Investment Research ©